Researchers from Northwestern University's Feinberg School of Medicine appear to have reversed the neurological dysfunction of early-stage multiple sclerosis patients by transplanting their own immune stem cells into their bodies and 
thereby "resetting" their immune systems.
"This is the first time we have turned the tide on this disease," said principal investigator Richard Burt, M.D. chief of immunotherapy for autoimmune diseases at the Feinberg School. The clinical trial was performed at Northwestern Memorial Hospital where Burt holds the same title.
The patients in the small phase I/II trial continued to improve for up to 24 months after the transplantation procedure and then stabilized. They experienced improvements in areas in which they had been affected by multiple sclerosis including walking, ataxia, limb strength, vision and incontinence. The study will be published online January 30 and in the March issue of The Lancet Neurology.
"We focus on destroying only the immune component of the bone marrow and then regenerate the immune component, which makes the procedure much safer and less toxic than traditional chemotherapy with cancer drugs," Burt said. After the transplantation, the patient's new lymphocytes or immune cells are self-tolerant and do not attack the immune system.
"In MS the immune system is attacking your brain," Burt said. "After the procedure, it doesn't do that anymore."
In previous studies, Burt had transplanted immune stem cells into late-stage MS patients. "It didn't help in the late stages, but when we treat them in the early stage, they get better and continue to get better," he said.
Source: EurekAlert!
Posts, Possibly of Interest
FDA: Skin Numbing Products Can Be Life Threatening
Top 13 Tips To Prevent Common Cold!
Vicks VapoRub Misuse May Harm Toddlers
Financial Crisis – Survival Tips for Small Medical Businesses
thereby "resetting" their immune systems."This is the first time we have turned the tide on this disease," said principal investigator Richard Burt, M.D. chief of immunotherapy for autoimmune diseases at the Feinberg School. The clinical trial was performed at Northwestern Memorial Hospital where Burt holds the same title.
The patients in the small phase I/II trial continued to improve for up to 24 months after the transplantation procedure and then stabilized. They experienced improvements in areas in which they had been affected by multiple sclerosis including walking, ataxia, limb strength, vision and incontinence. The study will be published online January 30 and in the March issue of The Lancet Neurology.
"We focus on destroying only the immune component of the bone marrow and then regenerate the immune component, which makes the procedure much safer and less toxic than traditional chemotherapy with cancer drugs," Burt said. After the transplantation, the patient's new lymphocytes or immune cells are self-tolerant and do not attack the immune system.
"In MS the immune system is attacking your brain," Burt said. "After the procedure, it doesn't do that anymore."
In previous studies, Burt had transplanted immune stem cells into late-stage MS patients. "It didn't help in the late stages, but when we treat them in the early stage, they get better and continue to get better," he said.
Source: EurekAlert!
Posts, Possibly of Interest
FDA: Skin Numbing Products Can Be Life Threatening
Top 13 Tips To Prevent Common Cold!
Vicks VapoRub Misuse May Harm Toddlers
Financial Crisis – Survival Tips for Small Medical Businesses
Posts
No comments:
Post a Comment